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Accurate TNM staging plays a pivotal role in cancer managementand research. The TNM staging system for esophageal cancer isfrequently viewed with discontent by thoracic surgeons. Yet, thesixth editions of the American Joint Committee on Cancer(AJCC) and the Union Internationale Contre le Cancer (UICC)staging manuals, published in 2002, offered minimal changes in
the chapter on esophageal staging.1,2 The AJCC chapter notes the remarkable
epidemiologic shift that has occurred in this disease with a rapid increase in the
number of adenocarcinomas of the distal esophagus and gastroesophageal junction.
The location of the lymph nodes involved by gastroesophageal junction tumors was
added to the section on nodal descriptors, and a lymph node map previously
proposed by Casson and colleagues3 was added to encourage uniform nomenclature
of lymph nodes removed at surgery. However, the TNM descriptors and stage
classifications were not changed from the previous editions of the staging manuals.
The lack of change in the esophageal staging system frustrates many surgeons
who believe that it does not stratify patients appropriately for prognosis. However,
a staging system must be evidence-based, prognostically accurate, easy to use, and
internationally accepted. The AJCC task force for the chapters on lung and esoph-
ageal cancer staging that I chaired1 strongly considered changing the staging system
for esophageal cancer, but in conjunction with the editors of the manual ultimately
did not do so because, unfortunately, there was insufficient published data to support
a proposal for a new system. In addition, the AJCC and the UICC coordinate
acceptance of changes in staging systems to maintain international concordance.
Proposed changes must be based on data considered persuasive by representatives
from all of the countries participating in the UICC. Such data did not exist at the
time the manual was being written.
In the current issue of the Journal, Rice and his colleagues4 at The Cleveland
Clinic proposed a revised staging system for esophageal cancer. In terms more
familiar to statisticians than to clinicians, their elegantly analyzed study examined
the “monotonicity, distinctiveness, and homogeneity of survival in the context of
current TNM classifications and stage groupings” based on a prospective 18-year
database of 480 patients treated solely by esophageal resection. Otherwise stated,
their analysis attempted to develop a staging system that reflects decreasing survival
across increasing tumor stages, distinct differences in survival for each of the stage
classifications, and no significant differences in survival among the TNM subsets
included within each stage category. Rice and coworkers modeled their study on the
pioneering approach used by Balch and colleagues5 in analyzing a large interna-
tional database to propose a new staging system for malignant melanoma—a system
that has just been adopted by the AJCC and UICC in the sixth editions of the staging
manuals. Balch’s approach set a new standard for the development of evidence-
based staging systems and has prompted similar efforts for other malignancies,
including a study recently initiated by the International Association for the Study of
Lung Cancer, aimed at achieving a comprehensive revision of the lung cancer
staging system.
Relative to the current staging system, the salient features of the system proposed
by Rice and coworkers include the following: the separation of T1 tumors into T1a
(intramucosal) and T1b (submucosal) with T1a and high-grade dysplasia grouped
together as stage I; a complete revision of the nodal descriptors based solely on the
number of involved lymph nodes (0 to 2 vs 3 or more) rather than anatomic lymph
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node location; and recategorization of TNM subsets within
just 4 stage classifications. The proposed change in the T
descriptors appropriately reflects the increasing experience
with very early cancers and our knowledge of the excellent
long-term survival after resection of these tumors. The
proposed revision of the N descriptors leads to a staging
system that is conceptually analogous to the gastric cancer
staging system, which ignores lymph node location and
considers only the number of metastatic lymph nodes, with
the caveat that at least 15 lymph nodes be removed for
adequate staging. Achieving some concordance between the
esophageal and gastric staging systems is important because
the number of distal gastric cancers and proximal esopha-
geal cancers is decreasing while the number of tumors
arising in the area of the gastroesophageal junction is in-
creasing. It is frequently very difficult to determine whether
these tumors arise from the gastric or the esophageal side of
the junction and which system should be used for staging.
The current N descriptors in the esophageal staging system
are also based on somewhat arbitrary definitions of what
constitute “regional” (N1) nodes as opposed to more “dis-
tant” metastatic nodes (M1a). However, we know that
lymph nodes metastases do not occur in this tightly defined
anatomic manner in esophageal cancer. And, as pointed out
by Rice and colleagues, the N1 versus M1a versus M1b
descriptors do not accurately identify prognostically differ-
ent groups.
Therefore, the study of Rice and coworkers is an impor-
tant and very welcome addition to the literature on esoph-
ageal staging. It benefits from prospective data acquisition,
a relatively large database, uniformity of patient treatment,
lack of confounding factors (for example, use of induction
therapy), and expert statistical analysis. The potential prog-
nostic importance of the number of metastatic lymph nodes
has been suggested by others previously.6 Additional stud-
ies from other institutions are needed to validate or modify
the proposed staging system. The changes in the T descrip-
tors are less likely to be controversial than those in the N
and M descriptors. Questions remain: Are the categories of
0 to 2 versus 3 or more lymph nodes adequate? Is there a
minimum number of lymph nodes or lymph node stations
that should be examined to achieve adequate staging? Are
there differences in this regard for the staging of distal
esophageal versus gastroesophageal junction versus gastric
cardia tumors? Should the M1 descriptor be reserved solely
for distant visceral metastases? Ideally, the excellent work
by Rice and colleagues will prompt other investigators to
pursue similar studies that will ultimately allow a clinically
meaningful revision of the esophageal staging system.
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